Late Gadolinium Enhancement in Cardiac MRI in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Systolic Function Is Related to Attenuated Improvement of Left Ventricular Geometry and Filling Pressure after Aortic Valve Replacement

Junbeom Park, MD, Hyuk-Jae Chang, MD, Jung-Ho Choi, MD, Pi-Sung Yang, MD, Sang-Eun Lee, MD, Ran Heo, MD, Sanghoon Shin, MD, In-Jeong Cho, MD, Young-Jin Kim, MD, Chi Young Shim, MD, Geu-Ru Hong, MD, and Namsik Chung, MD

1 Division of Cardiology and Radiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, 2 Severance Biomedical Science Institute, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea

Background and Objectives: We investigated echocardiographic predictors: left ventricular (LV) geometric changes following aortic valve replacement (AVR) according to the late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) in patients with severe aortic stenosis (AS) and preserved LV systolic function.

Subjects and Methods: We analyzed 41 patients (24 males, 63.1 ± 8.7 years) with preserved LV systolic function who were scheduled to undergo AVR for severe AS. All patients were examined with transthoracic echocardiography (TTE), CMR before and after AVR (in the hospital) and serial TTEs (at 6 and 12 months) were repeated.

Results: The group with LGE (LGE+) showed greater wall thickness (septum, 14.3 ± 2.6 mm vs. 11.5 ± 2.0 mm, p = 0.001, posterior; 14.3 ± 2.5 mm vs. 11.4 ± 1.6 mm, p < 0.001), lower tissue Doppler image (TDI, 4.4 ± 1.4 cm/s vs. 5.5 ± 1.2 cm/s, p = 0.021; TDI E', 3.2 ± 0.9 cm/s vs. 4.8 ± 1.4 cm/s, p = 0.002), and greater E/e' (21.8 ± 10.3 vs. 15.4 ± 6.3, p = 0.066) than those without LGE (LGE-). Multivariate analysis show that TDI E' (odds ratio = 0.078, 95% confidence interval = 0.007–0.888, p = 0.040) was an independent determinant of LGE+. In an analysis of the 6- and 12-month follow-up compared with pre-AVR, LGE- showed decreased LV end-diastolic diameter (48.3 ± 5.0 mm vs. 45.8 ± 3.6 mm, p = 0.027; 48.3 ± 5.0 mm vs. 46.5 ± 3.4 mm, p = 0.019). Moreover, E/e' (at 12 months) showed further improved LV filling pressure (16.0 ± 6.6 vs. 12.3 ± 4.3, p = 0.001) compared with pre-AVR. However, LGE+ showed no significant improvement.

Conclusion: The absence of LGE is associated with favorable improvements in LV geometry and filling pressure. TDI E' is an independent determinant of LGE in patients with severe AS and preserved LV systolic function. (Korean Circ J 2014;44(5):312–319)

KEY WORDS: Cardiac magnetic resonance imaging; Echocardiography; Aortic stenosis; Late gadolinium enhancement.

Introduction

Left ventricular (LV) systolic function is an independent predictor of outcome after aortic valve replacement (AVR) in patients with severe aortic stenosis (AS).1,2 Previous studies have mostly shown that patients with a reduced ejection fraction (EF) and severe AS have higher operative mortality and poor survival benefit versus those with normal EF.3-6 However, patients with reduced EF represent <5% of the population of patients with AS,7,8 and most patients who underwent AVR have preserved LV systolic function. Although dobutamine stress echocardiography is used for risk stratification of patients with reduced EF and severe AS,8,9 it is unclear what the best
method is in patients with preserved EF and severe AS. Severe AS causes LV pressure overload and results in myocardial fibrosis and impairment of myocyte ultrastructure.\(^5\)\(^-\)\(^10\) Also, it has been shown that the amount of myocardial fibrosis and myocyte degeneration affect LV systolic and diastolic dysfunction.\(^11\)\(^\text{12}\)\(^\text{13}\) With the development of cardiac magnetic resonance imaging (CMR), it was seen that late gadolinium enhancement (LGE) showed a good correlation with the degree of myocardial fibrosis by histopathology.\(^14\)\(^\text{15}\) Moreover, the amount of myocardial fibrosis was found to be an independent predictor of clinical outcome after AVR, and it had a meaningful association with LV functional remodeling.\(^14\)\(^\text{15}\) A problem with this analysis, however, is that histopathological measurement of fibrosis before AVR is too invasive for predicting long-term outcomes of patients with severe AS. Also, CMR comes at a high medical cost and cannot be used in patients with an intracardiac device. The purpose of our study was to investigate the differences between LV geometric changes following AVR according to the presence of LGE on CMR and to evaluate echocardiographic predictors of LGE in patients with severe AS and preserved LV systolic function.

**Subjects and Methods**

**Study population and protocol**

We enrolled 41 patients who were scheduled for an AVR due to severe AS, but who had preserved LV systolic function (EF \(\geq50\%\)) from January 2010 to April 2012. Severe AS was defined as having an aortic valve area \(\leq1.0\) cm\(^2\) and having symptoms such as dyspnea on exertion or syncope.\(^16\)\(^\text{17}\) All patients were evaluated by CMR, transthoracic echocardiography (TTE), and coronary angiography (CAG) before undergoing AVR. The exclusion criteria were any of the following: 1) having reduced LV systolic function (EF <50%), 2) having luminal narrowing of more than 50% by CAG, 3) having valvular disease more than grade I except AS, 4) having had a previous cardiac surgery, 5) having a history of percutaneous coronary intervention, or 6) having a history of myocardial infarction.

This study progressed prospectively after the enrollment of patients. All enrolled patients were evaluated by TTE, CMR, and CAG within 1 month before AVR, and the post-AVR TTE was conducted within 2 weeks after AVR (Fig. 1). Eight patients with EF <50% were excluded. Finally, 41 enrolled patients received follow-up appointments at an outpatient clinic. Repeat post-AVR TTEs were performed 6 months and 12 months after AVR.

This study protocol was approved by the Institutional Review Board of the Yonsei University Health System. All patients provided written informed consent.

**Standard echocardiographic measurements**

- **Chamber size** Left atrial volume index (LAVI), LA dimension, wall thickness of the LV, LV mass index (LVMI), and LV end diastolic dimension (LVEDD)/LV end systolic dimension (LVESD), \(E'\), flow pattern \(\{\text{trans mitral flow velocity (E wave, A wave), deceleration time}\}\), and tissue Doppler imaging (TDI) of the mitral annular septal area \{peak diastolic velocity (\(e'\)), peak systolic velocity (\(S'\))\} were measured according to the American Society of Echocardiography (ASE) guidelines.\(^16\)\(^\text{20}\) Two-dimensional echocardiographic assessment of LV volume and LV EF was performed in apical two- and four-chamber images. The endocardial border at both the end-diastolic and end-systolic frame was traced manually, and LV end diastolic volume (LVEDV), LV end-systolic volume (LVESV), and LVEF were calculated using the single-plane Simpson formula. LV mass was calculated from LV linear dimensions, as recommended by ASE. The posterior wall thickness (PWTd) and septal wall thickness were measured at end diastole. Relative wall thickness (RWT) was calculated with the formula \((2\times\text{PWTd})/\text{LVEDD}\). LAVI was also measured from the biplane method of disks (modified Simpson’s method) using apical two and four chamber views at ventricular end systole (maximum LA size). All echocardiographic parameters were determined by a sonographer who was blinded to the patient’s information. The results were confirmed by a second expert echocardiographer who was unaware of the patients’ clinical information.

**Magnetic resonance imaging protocol**

All patients underwent CMR within 1 month prior to AVR. CMR

---

**Fig. 1.** Evaluation of the progress of patients enrolled in the study. TTE: transthoracic echocardiography, CMR: cardiac magnetic resonance image, CAG: coronary angiography, AVR: aortic valve replacement, f/u: follow up, EF: ejection fraction.
was performed on a 1.5 T cardiac magnetic resonance system (Achieva 1.5 T; Philips Medical Systems 5680 DA, the Netherlands). The myocardium of the LV was evaluated in the short axis view and divided into base level (six segments), mid level (six segments) and apex (four segments). Consequently the entire myocardium of the LV was analyzed as a total of 16 segments (Fig. 2).

The appropriate inversion time of LGE CMR image was determined by inversion scout (TI-scout) with the Look-Locker technique. The mean inversion time for normal myocardium was 250–300 ms. All CMR (cine and LGE images) images of the entire LV were acquired with a 10-mm slice without a gap. The volume of the LV was determined by planimetry from a series of short-axis acquisitions covering the LV completely from the apex to the base. Quantification of LVESV, LVEDV, and EF were performed on the short-axis series with manual contour segmentation of the endocardial borders. The total LV stroke volume was obtained by subtracting the LV end-systolic volume from the LV end-diastolic volume. Each image was acquired 10–15 minutes after injection of 0.2 mmol/kg body weight gadoterate dimeglumine (Dotarem; Guerbet, Roissy CdG Cedex, Paris, France) to measure LGE from CMR. Endocardial and epicardial borders were traced semi-automatically, and LGE was defined as the pixels above the pre-determined threshold using the Q-MASS software (QMASS MR 7.4, Medis Medical Imaging Systems bv, Leiden, the Netherlands).

Statistical analyses
The normally distributed continuous variables are expressed as means±SD. We compared baseline characteristics and echocardiographic parameters between patients with and without LGE. Statistical significance (p<0.05) for comparisons was assessed using the unpaired two-tailed Student’s t-test for normally distributed continuous variables and the χ² test for nominal variables. All echocardiographic parameters were compared sequentially to the data from pre-AVR, post-AVR, 6-month follow-up, and 12-month follow-up analyses using a paired t-test and a mixed linear model according to the presence of LGE (significance defined as p<0.05).

Univariate and multivariate logistic regression analyses were used to confirm which echocardiographic parameters were associated with the presence of LGE (p<0.05). Variables selected for multivariate analysis were those with p<0.05 in the univariate analysis or were thought clinically to be associated with the presence of LGE. Variance inflation factors were used to measure co-linearity in multiple regression analyses.

Results
Baseline characteristics
In total, 49 patients were screened and eight with EF <50% were excluded before AVR. Finally 41 patients (24 males, 63.1±8.7 years) completed follow-up at 6 and 12 months post-AVR. LGE was detected in 12 (29.3%) patients. The main detection locations for LGE were the inferior wall (81.8%), the inferior septum (72.7%), and the mid-level (100%) of the LV (Fig. 3). Bicuspid AV was detected in 15 (36.6%) patients as the cause of AS.

Table 1 shows baseline characteristics for the initially enrolled patients.
Table 1. Baseline characteristics according to LGE by CMR

|                          | All (n=41) | LGE (-) (n=29) | LGE (+) (n=12) | p     |
|--------------------------|-----------|----------------|----------------|-------|
| Age (years)              | 63.1±8.7  | 62.1±9.1       | 65.4±7.5       | 0.278 |
| Male (n, %)              | 24 (58.5) | 17 (58.6)      | 7 (58.3)       | 0.987 |
| Diabetes mellitus (n, %) | 3 (7.3)   | 1 (3.4)        | 2 (16.7)       | 0.265 |
| Hypertension (n, %)      | 15 (36.6)| 9 (31.0)       | 6 (50.0)       | 0.212 |
| Dyslipidemia (n, %)      | 5 (12.2)  | 3 (10.3)       | 2 (16.7)       | 0.943 |
| Syncope Hx (n)           | 1         | 0              | 1              |       |
| NYHA III, IV (n, %)      | 24 (57.9) | 18 (62.1)      | 6 (50.0)       | 0.167 |
| Medication (pre-OP) (%)  |           |                |                |       |
| ACE inhibitor or ARB     | 12 (29.3) | 11 (37.0)      | 1 (8.3)        | 0.089 |
| Beta blocker             | 9 (22.0)  | 6 (20.7)       | 3 (25.0)       | 0.789 |
| Calcium channel blocker  | 7 (17.1)  | 4 (13.8)       | 3 (25.0)       | 0.383 |
| Medication (post-OP) (%) |           |                |                |       |
| ACE inhibitor or ARB     | 23 (56.1)| 16 (55.2)      | 7 (58.3)       | 0.956 |
| Beta blocker             | 20 (48.8)| 15 (52.0)      | 5 (41.7)       | 0.729 |
| Calcium channel blocker  | 11 (26.8)| 6 (20.7)       | 5 (41.7)       | 0.092 |
| Echocardiography         |           |                |                |       |
| RWMA (n, %)              | 0         | 0              | 0              | -     |
| Ejection fraction (%)    | 68.0±8.2  | 69.4±7.6       | 64.5±8.8       | 0.091 |
| LV end diastolic diameter (mm) | 47.9±5.3 | 48.5±5.0       | 46.6±5.9       | 0.336 |
| LV end systolic diameter (mm) | 30.9±4.9 | 30.8±4.6       | 31.4±5.8       | 0.744 |
| Peak aortic pressure gradient (mm Hg) | 87.9±31.4 | 83.7±32.9 | 97.9±26.4 | 0.214 |
| Mean aortic pressure gradient (mm Hg) | 55.6±20.4 | 52.8±20.0 | 62.2±20.8 | 0.205 |
| Aortic valve area (cm²)  | 0.7±0.3   | 0.7±0.3        | 0.7±0.2        | 0.486 |
| LV mass index (g/m²)     | 135.7±34.4| 127.7±33.1     | 156.0±30.4     | 0.019 |
| LA volume index (mL/m²)  | 38.5±20.8 | 38.1±23.2      | 39.5±14.1      | 0.858 |
| Deceleration time (ms)   | 237.3±53.5| 223.5±46.4     | 266.0±57.8     | 0.021 |
| E (cm/s)                 | 0.7±0.2   | 0.7±0.2        | 0.7±0.2        | 0.755 |
| A (cm/s)                 | 1.0±0.3   | 0.9±0.3        | 1.0±0.3        | 0.495 |
| TDI e (cm/s)'            | 4.3±1.5   | 4.8±1.4        | 3.2±0.9        | 0.002 |
| TDI A (cm/s)             | 7.6±2.2   | 8.1±1.9        | 6.4±2.4        | 0.041 |
| TDI S (cm/s)             | 5.1±1.4   | 5.5±1.2        | 4.4±1.4        | 0.021 |
| E/e'                     | 17.4±8.2  | 15.4±6.3       | 21.8±10.3      | 0.066 |
| CMR findings             |           |                |                |       |
| LVM (g)                  | 152.9±58.7| 144.1±60.0     | 172.2±55.6     | 0.347 |
| LVMI (g/m²)              | 83.8±36.6 | 74.3±34.5      | 102.7±36.0     | 0.123 |
| LVEDV (mL/BSA)           | 83.1±23.2 | 81.9±19.4      | 86.5±33.3      | 0.721 |
| LVESV (mL/BSA)           | 31.9±15.6 | 29.6±11.2      | 38.4±24.1      | 0.348 |
| LVM/LVEDV (g/mL)         | 1.2±0.6   | 1.0±0.4        | 1.5±0.8        | 0.087 |

Follow-up findings

|                          |           |                |                |       |
| SBP (mm Hg)              | 123.1±19.6| 121.2±19.6     | 127.9±19.6     | 0.343 |
| DBP (mm Hg)              | 75.7±12.0 | 75.0±12.3      | 77.4±11.5      | 0.595 |
| Mechanical valve (%)     | 20 (52.6) | 16 (59.3)      | 4 (36.4)       | 0.200 |
| Indexed EOA (cm²/m²)     | 1.1±0.2   | 1.1±0.3        | 1.0±0.2        | 0.384 |

LGE: late gadolinium enhancement, CMR: cardiac magnetic resonance image, NYHA: New York Heart Association, ACE: angiotensin converting enzyme, ARB: angiotensin receptor blocker, RWMA: regional wall motion abnormality, LV: left ventricle, LA: left atrial, TDI: tissue Doppler imaging, LVM: left ventricle mass, LVMI: left ventricle mass index, LVEDV: left ventricle end diastolic volume, LVESV: left ventricle end-systolic volume, SBP: systolic blood pressure, DBP: diastolic blood pressure, EOA: effective orifice area
patients. Neither age nor gender was significantly different between the two groups. Also, history of diabetes mellitus, hypertension, and dyslipidemia were similar in both groups. Use of medications that could have an effect on LV geometry and filling pressure did not differ significantly after the operation. However, echocardiographic findings showed significant differences between the two groups. The thickness of the inter-ventricular septum (14.3±2.6 mm vs. 11.5±2.0 mm, p=0.001) and of the LV posterior wall (14.3±2.5 mm vs. 11.4±1.6 mm, p<0.001) were greater in LGE+ patients.

Tissue Doppler imaging offered the most important findings: LGE+ patients had lower e’ (3.2±0.9 cm/s vs. 4.8±1.4 cm/s, p=0.002), S’ (4.4±1.4 cm/s vs. 5.5±1.2 cm/s, p=0.021), and higher E/e’ (21.8±10.3 vs. 15.4±6.3, p=0.066). However, the size of the cardiac chambers, the aortic valve area, and the pressure gradient via the aortic valve and LV systolic function were not significantly different (Table 1).

**Left ventricular remodeling after aortic valve replacement according to the presence of late gadolinium enhancement**

The sequentially measured post-AVR echocardiographic parameters were compared with those measured before AVR. LVEDD and RWT were decreased significantly after AVR in patients without LGE, but there was no significant decrease in patients with LGE. LVMI was decreased regardless of LGE (Fig. 4). E/e’, an index of LV filling pressure, was improved significantly in LGE- patients up to 12 months (from 16.0±6.6 to 12.3±4.3, p=0.001) after AVR. Also, E/e’ at 12 months showed a significant difference between LGE- and LGE+ (12.3±4.3 vs. 19.9±8.3, p=0.026) compared with those prior to AVR (15.4±6.3 vs. 21.8±10.3, p=0.066) (Fig. 5, Table 1). However, no improvement was observed of E/e’ in LGE+ patients. Additionally, increases in the LV EF showed no significant change between the groups through the 12-month follow-up period (Fig. 5).

**Multivariate logistic regression analysis on the presence of late gadolinium enhancement**

Tissue Doppler imaging e’ (odds ratio=0.078, 95% confidence interval=0.007–0.888, p=0.040) was independently associated with LGE by CMR in patients with severe AS (Table 2).

**Discussion**

This prospective study showed that the presence of LGE for risk stratification before AVR in patients with severe AS could play an...
Table 2. Multivariate logistic regression analysis on LGE by CMR

| Variable          | OR   | 95% CI         | p    |
|-------------------|------|----------------|------|
| Age               | 1.002| 0.828–1.214    | 0.981|
| Male              | 0.626| 0.046–8.610    | 0.726|
| Deceleration time | 1.016| 0.988–1.044    | 0.259|
| LVMI              | 1.023| 0.982–1.067    | 0.272|
| TDI S'            | 1.152| 0.202–6.576    | 0.873|
| TDI A'            | 0.591| 0.215–1.627    | 0.309|
| TDI e'            | 0.078| 0.007–0.888    | 0.040|
| Elc'              | 0.864| 0.591–1.264    | 0.453|

LGE: late gadolinium enhancement, CMR: cardiac magnetic resonance imaging, OR: odds ratio, CI: confidence interval, LVMI: left ventricular mass index, TDI: tissue Doppler imaging

Myocardial fibrosis by biopsy and late gadolinium enhancement by cardiac magnetic resonance imaging

Previous studies reported that LGE in CMR reflected myocardial fibrosis, as determined by histopathology, in patients with severe aortic valve disease, including aortic regurgitation. Additionally, LGE in CMR has also been found to indicate necrosis by myocardial ischemia, variable changes by non-ischemic cardiomyopathy, and hypertrophic cardiomyopathy, as well as myocardial fibrosis. A recent report showed that LGE measurements from CMR were overestimated versus the amount of fibrosis estimated by pathology. Moreover, myocardial fibrosis associated with severe AS did not show a diffuse pattern, but rather a patch-like appearance, and was usually located at the basal area of the LV. Based on these results, it can be concluded that cardiac biopsy to determine the presence of myocardial fibrosis before AVR will yield a high number of false negative results.

Late gadolinium enhancement by cardiac magnetic resonance imaging and left ventricular remodeling after aortic valve replacement

As mentioned previously, LV systolic function is an important predictor of operation mortality and clinical outcome. The risk stratification of patients with reduced EF and severe AS has been evaluated by various methods. However, although patients with preserved LV systolic function represent a large proportion of those with severe AS, evaluation for risk stratification prior to an operation is not enough. Furthermore, there has been no report showing a direct association between the presence of LGE and geometric remodeling of LV after AVR among patients with preserved LV systolic function.

The amount of myocardial fibrosis that was measured during the operation has an important association with long-term post-AVR outcome in patients with severe AS. With the availability of CMR, it is important to use LGE to determine risk stratification before AVR in patients with severe AS. This study showed that the presence of LGE was associated with poor improvement of LV geometry and filling pressure after AVR, especially in patients with preserved LV systolic function.

Clinical implications of echocardiography to predict late gadolinium enhancement and limitations of cardiac magnetic resonance imaging

Cardiac magnetic resonance imaging still has important limitations, such as its high medical cost, contraindication in patients with an intracardiac device, poor availability, and limited use in patients with claustrophobia. Thus, we compared echocardiographic parameters with the presence of LGE as measured by CMR. As mentioned in the American College of Cardiology/American Heart Association/European Society of Cardiology guidelines, most patients with severe AS experience AVR during the period in which EF is preserved (≥50%). In this study, the aortic valve area, pressure gradient, and the size of cardiac chambers did not differ significantly according to the presence of LGE. LV wall thickness also did not appear to have important implications, based on the multivariate analysis. In the analysis of tissue Doppler imaging, TDI e’ and S’ showed significant differences between patients with LGE and those without LGE. TDI e’ was independently associated with LGE after controlling related factors. Consequently, patients with severe AS and preserved LV systolic function also had reduced TDI e’, which suggests a diastolic abnormality of the LV and may be a surrogate marker of LGE in CMR.

Limitations

We analyzed the changes in LV geometry and the improvement of systolic function and filling pressure after AVR according to the presence of LGE in patients with severe AS and preserved LV systolic function. We did not, however, look for a difference according to the degree of LGE. Previous studies have classified ‘mild’ LGE according to the amount of LGE, but ‘mild’ LGE did not have any definite clinical implication in terms of risk stratification. Thus, further evaluations of the severity of LGE should be performed after...
the enrollment of additional patients. There was no mortality in our study after AVR during the 12 months of follow-up, so we could not analyze mortality outcomes according to the presence of LGE.

Conclusions
The presence of LGE, as measured with CMR, is associated with poor improvement of LV geometry and filling pressure after AVR in patients with severe AS and preserved LV systolic function. Reduced TDI E’ is an independent associate of LGE and can be measured noninvasively.

Acknowledgments
This work was supported by the IT R&D program of MSIP/KEIT (10044910, Development of Multi-modality Imaging and 3D Simulation-Based Integrative Diagnosis-Treatment Support Software System for Cardiovascular Diseases).

References
1. Czer LS, Gray RJ, Stewart ME, De Robertis M, Chaux A, Matloff JM. Reduction in sudden late death by concomitant revascularization with aortic valve replacement. J Thorac Cardiovasc Surg 1988;95:390-401.
2. Morris JJ, Schaff HV, Mullaney CJ, et al. Determinants of survival and recovery of left ventricular function after aortic valve replacement. Ann Thorac Surg 1993;56:22-9; discussion 29-30.
3. Smith N, McNulty JH, Rahimtoola SH. Severe aortic stenosis with impaired left ventricular function and clinical heart failure: results of valve replacement. Circulation 1978;58:255-64.
4. Connolly HM, Oh JK, Orszulak TA, et al. Aortic valve replacement for aortic stenosis with severe left ventricular dysfunction. Prognostic indicators. Circulation 1997;95:2395-400.
5. Tarantini G, Buja P, Scognamiglio R, et al. Aortic valve replacement in severe aortic stenosis with left ventricular dysfunction: determinants of cardiac mortality and ventricular function recovery. Eur J Cardiothorac Surg 2003;24:879-85.
6. Powell DE, Tunick PA, Rosenzweig BP, et al. Aortic valve replacement in patients with aortic stenosis and severe left ventricular dysfunction. Arch Intern Med 2000;160:1337-41.
7. Clavel MA, Fuchs C, Burwash IG, et al. Predictors of outcomes in low-flow, low-gradient aortic stenosis: results of the multicenter TOPAS Study. Circulation 2008;118(14 Suppl):S234-42.
8. Levy F, Laurent M, Monin JL, et al. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and long-term outcome: a European multicenter study. J Am Coll Cardiol 2008;51:1466-72.
9. Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984-91.
10. Kränenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 1989;79:744-55.
11. Maron BJ, Ferrans VJ, Roberts WC. Myocardial ultrastructure in patients with chronic aortic valve disease. Am J Cardiol 1975;35:725-39.
12. Villari B, Vassalli G, Monrad ES, Chiariello M, Turina M, Hess OM. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 1995;91:2353-8.
13. Hess OM, Ritter M, Schneider J, Grimm J, Turina M, Kränenbuehl HP. Diastolic stiffness and myocardial structure in aortic valve disease before and after valve replacement. Circulation 1984;69:855-65.
14. Weidemann F, Herrmann S, Störk S, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009;120:577-84.
15. Azevedo CF, Nigri M, Higuchi ML, et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 2010;56:278-87.
16. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008;118:e523-661.
17. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012;42:51-44.
18. Nagueh SF, Appleton CP, Gillette TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-33.
19. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
20. TTE/TEE Appropriateness Criteria Writing Group, Douglas PS, Khandheria B, et al. ACCF/ASE/ACPC/ASNC/SCACCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance. Endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Soc Echocardiogr 2007;20:787-805.
21. Hovda S, Rue H, Olstad B. New echocardiographic imaging method

http://dx.doi.org/10.4070/kcj.2014.44.5.312
based on the bandwidth of the ultrasound Doppler signal with applications in blood/tissue segmentation in the left ventricle. Comput Methods Programs Biomed 2008;92:279-88.

22. Bondarenko O, Beek AM, Hofman MB, et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson 2005;7:481-5.

23. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53.

24. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001;218:215-23.

25. Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001;357:21-8.

26. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005;26:1461-74.

27. Rochitte CE, Oliveira PF, Andrade JM, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease: a marker of disease severity. J Am Coll Cardiol 2005;46:1553-8.

28. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003;108:54-9.

29. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43:2260-4.